PARP inhibitor 2X-121
OV-121
Phase 2 small_molecule completed
Quick answer
PARP inhibitor 2X-121 for Metastatic Breast Cancer is a Phase 2 program (small_molecule) at Allarity Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Allarity Therapeutics
- Indication
- Metastatic Breast Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed